Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemiaJean‐Pierre J. Issa, Hagop M. Kantarjian, Guillermo Garcia‐Manero et al.|Cancer|2014Cited by 141
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Hagop M. Kantarjian, Jeffrey L. Jorgensen et al.|Cancer|2016Cited by 81
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemiaAziz Nazha, Stefan Faderl, Hagop M. Kantarjian et al.|American Journal of Hematology|2013Cited by 53
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemiaElias Jabbour, Hagop M. Kantarjian, Nicholas J. Short et al.|Cancer|2017Cited by 48
Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemiaTapan M. Kadia, Hagop M. Kantarjian, Stefan Faderl et al.|Cancer|2015Cited by 46